[HTML] jci.org

[HTML][HTML] PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks… - The Journal of …, 2013 - Am Soc Clin Investig
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …
被引用次数：267 相关文章

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

P Neviani, JG Harb, JJ Oaks… - Journal of Clinical …, 2013 - search.ebscohost.com
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

PP2A-activating drugs selectively eradicate tki-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks… - Journal of Clinical …, 2013 - augusta.elsevierpure.com
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks, R Santhanam… - Journal of Clinical …, 2013 - go.gale.com
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks… - Journal of Clinical …, 2013 - search.proquest.com
The success of tyrosine kinase inhibitors (TKI) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

[引用][C] PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks, R Santhanam… - Journal of Clinical …, 2013 - cir.nii.ac.jp
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

PP2A-activating drugs selectively eradicate tki-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks… - Journal of …, 2013 - mdanderson.elsevierpure.com
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks, R Santhanam… - THE JOURNAL OF …, 2013 - sfera.unife.it
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks… - The Journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …
[HTML] nih.gov

[HTML][HTML] PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

P Neviani, JG Harb, JJ Oaks, R Santhanam… - The Journal of …, 2013 - ncbi.nlm.nih.gov
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …